In a randomized phase III trial of sunitinib vs interferon-alfa (IFN-α) in metastatic renal cell carcinoma (mRCC), better baseline quality of life (QoL) was predictive of longer survival. Using this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback